FDA approves Pfizer's Inlyta for kidney cancer

(Reuters) - Pfizer's Inlyta drug for patients with advanced kidney cancer got the nod from U.S. regulators on Friday, boosting the company's plans to offset plunging Lipitor sales. The Food and Drug Administration said the drug, known gene...